Details of the Drug
General Information of Drug (ID: DM17TIX)
Drug Name |
1-Benzyl-1,2-dihydro-indazol-3-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-Benzyl-3-hydroxy-1H-indazole; 2215-63-6; 1-Benzyl-1H-indazol-3-ol; 1-Benzyl-1,2-dihydro-3H-indazol-3-one; 1-benzyl-2H-indazol-3-one; 1-Benzyl-1,2-dihydro-indazol-3-one; 1-benzylindazol-3-ol; CHEMBL8612; SXPJFDSMKWLOAB-UHFFFAOYSA-N; 3H-Indazol-3-one, 1,2-dihydro-1-(phenylmethyl)-; 1-Benzyl-2,3-dihydroindazol-3-one; CBMicro_007258; EINECS 218-680-4; 5-Hydroxybenzydamine; AC1Q6GZH; ACMC-1CR7T; ChemDiv2_000492; 1-Benzyl-3-hydroxyindazole; AC1Q6K7E; AC1L2O7R; Oprea1_591436; Oprea1_122894; MLS001211149; SCHEMBL376005
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 224.26 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||